<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00529165</url>
  </required_header>
  <id_info>
    <org_study_id>ISRCTN04277490</org_study_id>
    <nct_id>NCT00529165</nct_id>
  </id_info>
  <brief_title>The Necessity of an Injection-Meal-Interval in Patients With Type 2 Diabetes Mellitus and Therapy With Human Insulin</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Jena</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Jena</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to demonstrate, that there is no difference in metabolic control
      in patients with type 2 diabetes mellitus and therapy with human insulin with or without
      injection-meal-interval.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>Week 16 and 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemia</measure>
    <time_frame>Week 16 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment satisfaction</measure>
    <time_frame>week 16 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>week 16 and 28</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Diabetes Mellitus Type 2</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>with injection-meal-interval,cross over after 3 month, than without injection-meal-interval for 3 month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>without injection-meal-interval,cross over after 3 month, than with injection-meal-interval for 3 month</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>injection-meal-interval</intervention_name>
    <description>The patient injects human insulin (as Actrapid from NovoNordisc) as usual in their insulin routine. The injection is subcutaneous and the dosage is dependent on the blood glucose monitoring. Patients will inject insulin previous every meal, with the following differences:
Group A: with injection-meal-interval: 50 patients educated to inject the insulin with an injection-meal-interval of 15 minutes
Group B: without injection-meal-interval: 50 patients educated to inject the insulin without injection-meal-interval
Cross-over will occur to the other group after 12 weeks. The follow up is 28 weeks.</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes mellitus

          -  Aged 40 - 80 years

          -  Therapy with human insulin

        Exclusion Criteria:

          -  Pregnancy

          -  Nutrition disorders

          -  Psychological disease

          -  Body Mass Index (BMI) less than 25 kg/m^2

          -  HbA1c greater than 9%
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulrich A Mueller, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Jena, department of internal medicine III</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Friedrich-Schiller-University, department of internal medicine III</name>
      <address>
        <city>Jena</city>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2007</study_first_submitted>
  <study_first_submitted_qc>September 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2007</study_first_posted>
  <last_update_submitted>January 12, 2009</last_update_submitted>
  <last_update_submitted_qc>January 12, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2009</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. med. Ulrich Alfons MÃ¼ller</name_title>
    <organization>University Hospital Jena</organization>
  </responsible_party>
  <keyword>injection to meal time</keyword>
  <keyword>human insulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

